These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 16763282)

  • 1. Systemic therapy in the palliative management of advanced salivary gland cancers.
    Laurie SA; Licitra L
    J Clin Oncol; 2006 Jun; 24(17):2673-8. PubMed ID: 16763282
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systemic therapies for recurrent and/or metastatic salivary gland cancers.
    Vattemi E; Graiff C; Sava T; Pedersini R; Caldara A; Mandarà M
    Expert Rev Anticancer Ther; 2008 Mar; 8(3):393-402. PubMed ID: 18366287
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical trial of nintedanib in patients with recurrent or metastatic salivary gland cancer of the head and neck: A multicenter phase 2 study (Korean Cancer Study Group HN14-01).
    Kim Y; Lee SJ; Lee JY; Lee SH; Sun JM; Park K; An HJ; Cho JY; Kang EJ; Lee HY; Kim J; Keam B; Kim HR; Lee KE; Choi MY; Lee KH; Ahn MJ
    Cancer; 2017 Jun; 123(11):1958-1964. PubMed ID: 28102887
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase II study of sorafenib in recurrent and/or metastatic salivary gland carcinomas: Translational analyses and clinical impact.
    Locati LD; Perrone F; Cortelazzi B; Bergamini C; Bossi P; Civelli E; Morosi C; Lo Vullo S; Imbimbo M; Quattrone P; Dagrada GP; Granata R; Resteghini C; Mirabile A; Alfieri S; Orlandi E; Mariani L; Saibene G; Pilotti S; Licitra L
    Eur J Cancer; 2016 Dec; 69():158-165. PubMed ID: 27821319
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of minor salivary gland carcinomas.
    Eschwege F
    Int J Radiat Oncol Biol Phys; 1996 Jun; 35(3):631-2. PubMed ID: 8655391
    [No Abstract]   [Full Text] [Related]  

  • 6. Phase II study of gefitinib in patients with advanced salivary gland cancers.
    Jakob JA; Kies MS; Glisson BS; Kupferman ME; Liu DD; Lee JJ; El-Naggar AK; Gonzalez-Angulo AM; Blumenschein GR
    Head Neck; 2015 May; 37(5):644-9. PubMed ID: 24585506
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Salivary gland cancers: biology and molecular targets for therapy.
    Bell D; Hanna EY
    Curr Oncol Rep; 2012 Apr; 14(2):166-74. PubMed ID: 22246609
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Androgen receptor in salivary gland carcinoma: A review of an old marker as a possible new target.
    Yeoh CC; Dabab N; Rigby E; Chhikara R; Akaev I; Gomez RS; Fonseca F; Brennan PA; Rahimi S
    J Oral Pathol Med; 2018 Aug; 47(7):691-695. PubMed ID: 29863801
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glands.
    Agulnik M; Cohen EW; Cohen RB; Chen EX; Vokes EE; Hotte SJ; Winquist E; Laurie S; Hayes DN; Dancey JE; Brown S; Pond GR; Lorimer I; Daneshmand M; Ho J; Tsao MS; Siu LL
    J Clin Oncol; 2007 Sep; 25(25):3978-84. PubMed ID: 17761983
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human epidermal receptor 2-amplified salivary duct carcinoma: regression with dual human epidermal receptor 2 inhibition and anti-vascular endothelial growth factor combination treatment.
    Falchook GS; Lippman SM; Bastida CC; Kurzrock R
    Head Neck; 2014 Mar; 36(3):E25-7. PubMed ID: 23852769
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systemic therapy in the management of recurrent or metastatic salivary duct carcinoma: A systematic review.
    Uijen MJM; Lassche G; van Engen-van Grunsven ACH; Tada Y; Verhaegh GW; Schalken JA; Driessen CML; van Herpen CML
    Cancer Treat Rev; 2020 Sep; 89():102069. PubMed ID: 32717621
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Palliative chemotherapy in patients with salivary gland neoplasms and preliminary reports of 2 recent phase II studies with trastuzumab and gemcitabine.
    Haddad R; Posner MR
    Clin Adv Hematol Oncol; 2003 Apr; 1(4):226-8. PubMed ID: 16224411
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II trial of taxol in salivary gland malignancies (E1394): a trial of the Eastern Cooperative Oncology Group.
    Gilbert J; Li Y; Pinto HA; Jennings T; Kies MS; Silverman P; Forastiere AA
    Head Neck; 2006 Mar; 28(3):197-204. PubMed ID: 16470745
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systemic therapy in the management of metastatic or advanced salivary gland cancers.
    Lagha A; Chraiet N; Ayadi M; Krimi S; Allani B; Rifi H; Raies H; Mezlini A
    Oral Oncol; 2012 Oct; 48(10):948-957. PubMed ID: 22698431
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systemic therapy in the management of metastatic or locally recurrent adenoid cystic carcinoma of the salivary glands: a systematic review.
    Laurie SA; Ho AL; Fury MG; Sherman E; Pfister DG
    Lancet Oncol; 2011 Aug; 12(8):815-24. PubMed ID: 21147032
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cyclophosphamide, doxorubicin, and cisplatin in advanced salivary gland cancer.
    Debaere D; Vander Poorten V; Nuyts S; Hauben E; Schoenaers J; Schöffski P; Clement PM
    B-ENT; 2011; 7(1):1-6. PubMed ID: 21563549
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Salivary gland cancers: current treatments, molecular characteristics and new therapies.
    Chandana SR; Conley BA
    Expert Rev Anticancer Ther; 2008 Apr; 8(4):645-52. PubMed ID: 18402531
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemotherapy for salivary gland cancer.
    Kaplan MJ; Johns ME; Cantrell RW
    Otolaryngol Head Neck Surg; 1986 Sep; 95(2):165-70. PubMed ID: 3035459
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epithelial tumors of the lacrimal glands: a clinicopathologic study.
    Paulino AF; Huvos AG
    Ann Diagn Pathol; 1999 Aug; 3(4):199-204. PubMed ID: 10459045
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Carcinoma of the salivary glands: guidelines and case report of sustained remission with docetaxel.
    Arrondeau J; Le Nagat S; Lefèvre M; Tassart M; Touboul E; Lacau St Guily J; Huguet F
    J Clin Pharm Ther; 2015 Feb; 40(1):116-8. PubMed ID: 25302593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.